Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer

PURPOSE: BRAF mutation occurs in 8–15% of colon cancers (CC), and is associated with poor prognosis in metastatic disease. Compared to wild-type BRAF (BRAFWT) disease, stage II/III CC patients with BRAF mutant (BRAFMT) tumors have shorter overall survival after relapse; however, time-to-relapse is n...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunne, Philip D., Coleman, Helen G., Bankhead, Peter, Alderdice, Matthew, Gray, Ronan T., McQuaid, Stephen, Bingham, Victoria, Loughrey, Maurice B., James, Jacqueline A., McCorry, Amy M.B., Gilmore, Alan, Holohan, Caitriona, Klingbiel, Dirk, Tejpar, Sabine, Johnston, Patrick G., McArt, Darragh G., Nicolantonio, Federica Di, Longley, Daniel B., Lawler, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862619/
https://www.ncbi.nlm.nih.gov/pubmed/29568398
http://dx.doi.org/10.18632/oncotarget.24481

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862619/
https://www.ncbi.nlm.nih.gov/pubmed/29568398
http://dx.doi.org/10.18632/oncotarget.24481

Ejemplares similares